Structure Therapeutics Inc. (GPCR) Statistics & Valuation Metrics - Stocknear

Structure Therapeutics In...

NASDAQ: GPCR · Real-Time Price · USD
20.57
-0.34 (-1.63%)
At close: Sep 15, 2025, 9:50 AM

Structure Therapeutics Statistics

Share Statistics

Structure Therapeutics has 57.57M shares outstanding. The number of shares has increased by 4.31% in one year.

57.57M
4.31%
0.44%
9.76%
54.72M
65,854
7.33%

Short Selling Information

The latest short interest is 7.26M, so 12.6% of the outstanding shares have been sold short.

7.26M
12.6%
18.17%
6.79

Valuation Ratios

The PE ratio is -11.65 and the forward PE ratio is -12.22. Structure Therapeutics's PEG ratio is 3.15.

-11.65
-12.22
0
n/a
1.65
-12.11
3.15
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Structure Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 24.74, with a Debt / Equity ratio of 0.

24.74
24.74
0
-0.02
-0.03
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-751.69K
163
0
n/a

Taxes

310K
-0.25%

Stock Price Statistics

The stock price has increased by -48.8% in the last 52 weeks. The beta is -1.99, so Structure Therapeutics's price volatility has been lower than the market average.

-1.99
-48.8%
18.92
23.19
58.61
898,424

Income Statement

n/a
-2.6M
-158.23M
-122.53M
-158.23M
-158.23M
-2.34
Full Income Statement

Balance Sheet

The company has 169.51M in cash and 3.86M in debt, giving a net cash position of 165.65M.

169.51M
3.86M
165.65M
-329.1M
816.46M
760.28M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -116.64M and capital expenditures -1.29M, giving a free cash flow of -117.93M.

-116.64M
-1.29M
-117.93M
-2.24
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

GPCR does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for GPCR is $76, which is 263.5% higher than the current price. The consensus rating is "Buy".

$76
263.5%
Buy
8
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

16.06
2